nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PLK3—pancreas—gallbladder cancer	0.00884	0.0281	CbGeAlD
Ruxolitinib—JAK1—epithelium—gallbladder cancer	0.00761	0.0242	CbGeAlD
Ruxolitinib—PRKG2—liver—gallbladder cancer	0.00751	0.0239	CbGeAlD
Ruxolitinib—PRKCE—liver—gallbladder cancer	0.00701	0.0223	CbGeAlD
Ruxolitinib—JAK1—pancreas—gallbladder cancer	0.00678	0.0216	CbGeAlD
Ruxolitinib—PLK1—liver—gallbladder cancer	0.00674	0.0214	CbGeAlD
Ruxolitinib—RPS6KA6—liver—gallbladder cancer	0.00674	0.0214	CbGeAlD
Ruxolitinib—CAMK1D—pancreas—gallbladder cancer	0.00662	0.0211	CbGeAlD
Ruxolitinib—ROCK1—epithelium—gallbladder cancer	0.00656	0.0209	CbGeAlD
Ruxolitinib—HIPK2—pancreas—gallbladder cancer	0.00633	0.0201	CbGeAlD
Ruxolitinib—DAPK3—pancreas—gallbladder cancer	0.00608	0.0194	CbGeAlD
Ruxolitinib—PLK3—liver—gallbladder cancer	0.00562	0.0179	CbGeAlD
Ruxolitinib—NUAK2—pancreas—gallbladder cancer	0.00542	0.0173	CbGeAlD
Ruxolitinib—PRKCE—lymph node—gallbladder cancer	0.00538	0.0171	CbGeAlD
Ruxolitinib—CAMK1—liver—gallbladder cancer	0.00526	0.0167	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—gallbladder cancer	0.00517	0.0164	CbGeAlD
Ruxolitinib—PLK1—lymph node—gallbladder cancer	0.00517	0.0164	CbGeAlD
Ruxolitinib—CAMK2G—pancreas—gallbladder cancer	0.00508	0.0162	CbGeAlD
Ruxolitinib—MKNK2—epithelium—gallbladder cancer	0.00497	0.0158	CbGeAlD
Ruxolitinib—RET—epithelium—gallbladder cancer	0.00485	0.0154	CbGeAlD
Ruxolitinib—TAOK2—liver—gallbladder cancer	0.00473	0.015	CbGeAlD
Ruxolitinib—JAK2—epithelium—gallbladder cancer	0.00458	0.0146	CbGeAlD
Ruxolitinib—TYK2—pancreas—gallbladder cancer	0.00448	0.0143	CbGeAlD
Ruxolitinib—MKNK2—pancreas—gallbladder cancer	0.00443	0.0141	CbGeAlD
Ruxolitinib—IRAK1—pancreas—gallbladder cancer	0.00443	0.0141	CbGeAlD
Ruxolitinib—JAK1—liver—gallbladder cancer	0.00432	0.0137	CbGeAlD
Ruxolitinib—PLK3—lymph node—gallbladder cancer	0.00431	0.0137	CbGeAlD
Ruxolitinib—CAMK1D—liver—gallbladder cancer	0.00421	0.0134	CbGeAlD
Ruxolitinib—PHKG2—liver—gallbladder cancer	0.00419	0.0133	CbGeAlD
Ruxolitinib—LTK—lymph node—gallbladder cancer	0.00417	0.0133	CbGeAlD
Ruxolitinib—STK16—liver—gallbladder cancer	0.00405	0.0129	CbGeAlD
Ruxolitinib—CAMK1—lymph node—gallbladder cancer	0.00403	0.0128	CbGeAlD
Ruxolitinib—HIPK2—liver—gallbladder cancer	0.00403	0.0128	CbGeAlD
Ruxolitinib—MARK2—lymph node—gallbladder cancer	0.00392	0.0125	CbGeAlD
Ruxolitinib—DAPK3—liver—gallbladder cancer	0.00387	0.0123	CbGeAlD
Ruxolitinib—CLK2—liver—gallbladder cancer	0.00383	0.0122	CbGeAlD
Ruxolitinib—ROCK1—liver—gallbladder cancer	0.00372	0.0118	CbGeAlD
Ruxolitinib—DYRK1A—liver—gallbladder cancer	0.00362	0.0115	CbGeAlD
Ruxolitinib—TAOK2—lymph node—gallbladder cancer	0.00362	0.0115	CbGeAlD
Ruxolitinib—BMPR2—liver—gallbladder cancer	0.00361	0.0115	CbGeAlD
Ruxolitinib—TAOK3—pancreas—gallbladder cancer	0.00359	0.0114	CbGeAlD
Ruxolitinib—NUAK2—liver—gallbladder cancer	0.00345	0.011	CbGeAlD
Ruxolitinib—JAK3—lymph node—gallbladder cancer	0.00333	0.0106	CbGeAlD
Ruxolitinib—DCLK1—lymph node—gallbladder cancer	0.00331	0.0105	CbGeAlD
Ruxolitinib—JAK1—lymph node—gallbladder cancer	0.00331	0.0105	CbGeAlD
Ruxolitinib—PLK4—lymph node—gallbladder cancer	0.00329	0.0105	CbGeAlD
Ruxolitinib—BMP2K—liver—gallbladder cancer	0.00323	0.0103	CbGeAlD
Ruxolitinib—CAMK2G—liver—gallbladder cancer	0.00323	0.0103	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—gallbladder cancer	0.00323	0.0103	CbGeAlD
Ruxolitinib—PHKG2—lymph node—gallbladder cancer	0.00321	0.0102	CbGeAlD
Ruxolitinib—LRRK2—liver—gallbladder cancer	0.0032	0.0102	CbGeAlD
Ruxolitinib—DAPK2—lymph node—gallbladder cancer	0.00316	0.01	CbGeAlD
Ruxolitinib—STK16—lymph node—gallbladder cancer	0.00311	0.00988	CbGeAlD
Ruxolitinib—HIPK2—lymph node—gallbladder cancer	0.00309	0.00983	CbGeAlD
Ruxolitinib—DAPK3—lymph node—gallbladder cancer	0.00297	0.00944	CbGeAlD
Ruxolitinib—CLK2—lymph node—gallbladder cancer	0.00294	0.00935	CbGeAlD
Ruxolitinib—MAP3K2—liver—gallbladder cancer	0.00293	0.00933	CbGeAlD
Ruxolitinib—MAP3K7—liver—gallbladder cancer	0.00291	0.00925	CbGeAlD
Ruxolitinib—TYK2—liver—gallbladder cancer	0.00285	0.00908	CbGeAlD
Ruxolitinib—MKNK2—liver—gallbladder cancer	0.00282	0.00896	CbGeAlD
Ruxolitinib—IRAK1—liver—gallbladder cancer	0.00282	0.00896	CbGeAlD
Ruxolitinib—DYRK1A—lymph node—gallbladder cancer	0.00278	0.00884	CbGeAlD
Ruxolitinib—BMPR2—lymph node—gallbladder cancer	0.00277	0.00881	CbGeAlD
Ruxolitinib—NUAK2—lymph node—gallbladder cancer	0.00265	0.00842	CbGeAlD
Ruxolitinib—JAK2—liver—gallbladder cancer	0.0026	0.00826	CbGeAlD
Ruxolitinib—MAP3K3—liver—gallbladder cancer	0.0025	0.00796	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—gallbladder cancer	0.00248	0.00788	CbGeAlD
Ruxolitinib—BMP2K—lymph node—gallbladder cancer	0.00248	0.00788	CbGeAlD
Ruxolitinib—LRRK2—lymph node—gallbladder cancer	0.00245	0.00781	CbGeAlD
Ruxolitinib—TAOK3—liver—gallbladder cancer	0.00228	0.00726	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—gallbladder cancer	0.00225	0.00716	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—gallbladder cancer	0.00223	0.00709	CbGeAlD
Ruxolitinib—TYK2—lymph node—gallbladder cancer	0.00219	0.00696	CbGeAlD
Ruxolitinib—MKNK2—lymph node—gallbladder cancer	0.00216	0.00687	CbGeAlD
Ruxolitinib—IRAK1—lymph node—gallbladder cancer	0.00216	0.00687	CbGeAlD
Ruxolitinib—RET—lymph node—gallbladder cancer	0.00211	0.0067	CbGeAlD
Ruxolitinib—JAK2—lymph node—gallbladder cancer	0.00199	0.00633	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—gallbladder cancer	0.00192	0.0061	CbGeAlD
Ruxolitinib—TAOK3—lymph node—gallbladder cancer	0.00175	0.00557	CbGeAlD
Ruxolitinib—CYP3A4—liver—gallbladder cancer	0.000693	0.00221	CbGeAlD
Ruxolitinib—PHKG2—Disease—KRAS—gallbladder cancer	0.000105	0.000154	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—NRAS—gallbladder cancer	0.000105	0.000154	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling by NGF—HRAS—gallbladder cancer	0.000105	0.000153	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—KRAS—gallbladder cancer	0.000105	0.000153	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—ERBB2—gallbladder cancer	0.000105	0.000152	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—BCL2—gallbladder cancer	0.000104	0.000152	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—ERBB2—gallbladder cancer	0.000104	0.000152	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—BCL2—gallbladder cancer	0.000104	0.000152	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—ERBB2—gallbladder cancer	0.000104	0.000151	CbGpPWpGaD
Ruxolitinib—TYK2—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.000103	0.000151	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB4—gallbladder cancer	0.000103	0.000151	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—KRAS—gallbladder cancer	0.000103	0.00015	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—KRAS—gallbladder cancer	0.000103	0.00015	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by NGF—HRAS—gallbladder cancer	0.000102	0.000148	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—HRAS—gallbladder cancer	0.000101	0.000148	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—ERBB2—gallbladder cancer	0.000101	0.000148	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—ERBB2—gallbladder cancer	0.000101	0.000147	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—NRAS—gallbladder cancer	0.000101	0.000147	CbGpPWpGaD
Ruxolitinib—MAP3K7—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.0001	0.000146	CbGpPWpGaD
Ruxolitinib—JAK2—NGF signalling via TRKA from the plasma membrane—HRAS—gallbladder cancer	0.0001	0.000146	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB3—gallbladder cancer	9.97e-05	0.000145	CbGpPWpGaD
Ruxolitinib—GRK1—Disease—HRAS—gallbladder cancer	9.91e-05	0.000145	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB3—gallbladder cancer	9.86e-05	0.000144	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—BCL2—gallbladder cancer	9.84e-05	0.000143	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB4—gallbladder cancer	9.81e-05	0.000143	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EGFR—gallbladder cancer	9.79e-05	0.000143	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—ERBB2—gallbladder cancer	9.71e-05	0.000142	CbGpPWpGaD
Ruxolitinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	9.68e-05	0.000141	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB3—gallbladder cancer	9.68e-05	0.000141	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB4—gallbladder cancer	9.65e-05	0.000141	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—EGFR—gallbladder cancer	9.6e-05	0.00014	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—ERBB2—gallbladder cancer	9.56e-05	0.000139	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—NRAS—gallbladder cancer	9.54e-05	0.000139	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—NRAS—gallbladder cancer	9.49e-05	0.000138	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—NRAS—gallbladder cancer	9.43e-05	0.000138	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB3—gallbladder cancer	9.39e-05	0.000137	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—KRAS—gallbladder cancer	9.24e-05	0.000135	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—KRAS—gallbladder cancer	9.22e-05	0.000135	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—HRAS—gallbladder cancer	9.2e-05	0.000134	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EGFR—gallbladder cancer	9.19e-05	0.000134	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—gallbladder cancer	9.13e-05	0.000133	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—KRAS—gallbladder cancer	9.07e-05	0.000132	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—NRAS—gallbladder cancer	8.98e-05	0.000131	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—HRAS—gallbladder cancer	8.96e-05	0.000131	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—ERBB2—gallbladder cancer	8.94e-05	0.00013	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB3—gallbladder cancer	8.94e-05	0.00013	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—HRAS—gallbladder cancer	8.9e-05	0.00013	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—HRAS—gallbladder cancer	8.75e-05	0.000128	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—HRAS—gallbladder cancer	8.73e-05	0.000127	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—gallbladder cancer	8.69e-05	0.000127	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—KRAS—gallbladder cancer	8.69e-05	0.000127	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—gallbladder cancer	8.64e-05	0.000126	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—NRAS—gallbladder cancer	8.62e-05	0.000126	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—gallbladder cancer	8.59e-05	0.000125	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—NRAS—gallbladder cancer	8.58e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB4—gallbladder cancer	8.49e-05	0.000124	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB3—gallbladder cancer	8.48e-05	0.000124	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—BCL2—gallbladder cancer	8.46e-05	0.000123	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB3—gallbladder cancer	8.34e-05	0.000122	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—ERBB2—gallbladder cancer	8.22e-05	0.00012	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—KRAS—gallbladder cancer	8.21e-05	0.00012	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—gallbladder cancer	8.18e-05	0.000119	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—NRAS—gallbladder cancer	8.17e-05	0.000119	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—KRAS—gallbladder cancer	8.17e-05	0.000119	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—BCL2—gallbladder cancer	8.13e-05	0.000119	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—KRAS—gallbladder cancer	8.12e-05	0.000118	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—NRAS—gallbladder cancer	7.96e-05	0.000116	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—NRAS—gallbladder cancer	7.96e-05	0.000116	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—NRAS—gallbladder cancer	7.93e-05	0.000116	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—ERBB2—gallbladder cancer	7.9e-05	0.000115	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—NRAS—gallbladder cancer	7.89e-05	0.000115	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—HRAS—gallbladder cancer	7.86e-05	0.000115	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—gallbladder cancer	7.85e-05	0.000114	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	7.84e-05	0.000114	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB4—gallbladder cancer	7.84e-05	0.000114	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—gallbladder cancer	7.82e-05	0.000114	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—KRAS—gallbladder cancer	7.73e-05	0.000113	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—gallbladder cancer	7.72e-05	0.000113	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—NRAS—gallbladder cancer	7.71e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—HRAS—gallbladder cancer	7.71e-05	0.000112	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—NRAS—gallbladder cancer	7.69e-05	0.000112	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—ERBB2—gallbladder cancer	7.59e-05	0.000111	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB4—gallbladder cancer	7.46e-05	0.000109	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—gallbladder cancer	7.44e-05	0.000109	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—KRAS—gallbladder cancer	7.42e-05	0.000108	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—KRAS—gallbladder cancer	7.39e-05	0.000108	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—NRAS—gallbladder cancer	7.39e-05	0.000108	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—HRAS—gallbladder cancer	7.38e-05	0.000108	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB3—gallbladder cancer	7.34e-05	0.000107	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—ERBB2—gallbladder cancer	7.32e-05	0.000107	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—NRAS—gallbladder cancer	7.27e-05	0.000106	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—gallbladder cancer	7.26e-05	0.000106	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—gallbladder cancer	7.25e-05	0.000106	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—gallbladder cancer	7.25e-05	0.000106	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB4—gallbladder cancer	7.24e-05	0.000106	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—gallbladder cancer	7.22e-05	0.000105	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—gallbladder cancer	7.19e-05	0.000105	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—KRAS—gallbladder cancer	7.03e-05	0.000103	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—gallbladder cancer	7.02e-05	0.000102	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB4—gallbladder cancer	7.02e-05	0.000102	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—gallbladder cancer	7.01e-05	0.000102	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—HRAS—gallbladder cancer	6.98e-05	0.000102	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—HRAS—gallbladder cancer	6.94e-05	0.000101	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—HRAS—gallbladder cancer	6.9e-05	0.000101	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—KRAS—gallbladder cancer	6.85e-05	9.99e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—KRAS—gallbladder cancer	6.85e-05	9.99e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—NRAS—gallbladder cancer	6.85e-05	9.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—KRAS—gallbladder cancer	6.82e-05	9.95e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—NRAS—gallbladder cancer	6.8e-05	9.92e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—KRAS—gallbladder cancer	6.79e-05	9.91e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB3—gallbladder cancer	6.77e-05	9.88e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—NRAS—gallbladder cancer	6.73e-05	9.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—gallbladder cancer	6.73e-05	9.81e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—NRAS—gallbladder cancer	6.67e-05	9.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—KRAS—gallbladder cancer	6.64e-05	9.68e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—gallbladder cancer	6.63e-05	9.66e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—KRAS—gallbladder cancer	6.62e-05	9.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—HRAS—gallbladder cancer	6.57e-05	9.58e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—gallbladder cancer	6.56e-05	9.57e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB3—gallbladder cancer	6.45e-05	9.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—BCL2—gallbladder cancer	6.44e-05	9.39e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—KRAS—gallbladder cancer	6.36e-05	9.27e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—HRAS—gallbladder cancer	6.3e-05	9.19e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—HRAS—gallbladder cancer	6.28e-05	9.15e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB3—gallbladder cancer	6.26e-05	9.13e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—KRAS—gallbladder cancer	6.26e-05	9.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—NRAS—gallbladder cancer	6.26e-05	9.12e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—ERBB2—gallbladder cancer	6.25e-05	9.12e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—BCL2—gallbladder cancer	6.25e-05	9.11e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—gallbladder cancer	6.24e-05	9.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—gallbladder cancer	6.2e-05	9.04e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—ERBB2—gallbladder cancer	6.18e-05	9.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—gallbladder cancer	6.14e-05	8.95e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB3—gallbladder cancer	6.07e-05	8.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—ERBB2—gallbladder cancer	6.07e-05	8.85e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—BCL2—gallbladder cancer	6.06e-05	8.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—NRAS—gallbladder cancer	6.01e-05	8.76e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—HRAS—gallbladder cancer	5.98e-05	8.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—KRAS—gallbladder cancer	5.89e-05	8.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—ERBB2—gallbladder cancer	5.89e-05	8.59e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—KRAS—gallbladder cancer	5.86e-05	8.54e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—HRAS—gallbladder cancer	5.82e-05	8.49e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—HRAS—gallbladder cancer	5.82e-05	8.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—HRAS—gallbladder cancer	5.8e-05	8.46e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—KRAS—gallbladder cancer	5.8e-05	8.45e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NRAS—gallbladder cancer	5.78e-05	8.42e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—HRAS—gallbladder cancer	5.77e-05	8.42e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—KRAS—gallbladder cancer	5.74e-05	8.38e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—gallbladder cancer	5.7e-05	8.31e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—HRAS—gallbladder cancer	5.64e-05	8.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—HRAS—gallbladder cancer	5.63e-05	8.21e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—ERBB2—gallbladder cancer	5.6e-05	8.17e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NRAS—gallbladder cancer	5.57e-05	8.12e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB4—gallbladder cancer	5.49e-05	8e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—gallbladder cancer	5.47e-05	7.98e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—HRAS—gallbladder cancer	5.4e-05	7.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—KRAS—gallbladder cancer	5.38e-05	7.85e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—HRAS—gallbladder cancer	5.32e-05	7.76e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—ERBB2—gallbladder cancer	5.32e-05	7.75e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—gallbladder cancer	5.26e-05	7.67e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—ERBB2—gallbladder cancer	5.23e-05	7.63e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—KRAS—gallbladder cancer	5.17e-05	7.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—gallbladder cancer	5.11e-05	7.45e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—gallbladder cancer	5.08e-05	7.4e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—NRAS—gallbladder cancer	5.05e-05	7.37e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—HRAS—gallbladder cancer	5.01e-05	7.3e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—HRAS—gallbladder cancer	4.98e-05	7.26e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—KRAS—gallbladder cancer	4.97e-05	7.25e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—HRAS—gallbladder cancer	4.93e-05	7.18e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—HRAS—gallbladder cancer	4.88e-05	7.12e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—KRAS—gallbladder cancer	4.79e-05	6.99e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—NRAS—gallbladder cancer	4.76e-05	6.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB3—gallbladder cancer	4.74e-05	6.92e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—gallbladder cancer	4.74e-05	6.91e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NRAS—gallbladder cancer	4.7e-05	6.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—NRAS—gallbladder cancer	4.62e-05	6.74e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—gallbladder cancer	4.61e-05	6.72e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—ERBB2—gallbladder cancer	4.6e-05	6.71e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—HRAS—gallbladder cancer	4.58e-05	6.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—NRAS—gallbladder cancer	4.48e-05	6.53e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—HRAS—gallbladder cancer	4.4e-05	6.41e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—KRAS—gallbladder cancer	4.35e-05	6.34e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—gallbladder cancer	4.33e-05	6.32e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—gallbladder cancer	4.28e-05	6.25e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NRAS—gallbladder cancer	4.26e-05	6.22e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—gallbladder cancer	4.26e-05	6.21e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—ERBB2—gallbladder cancer	4.25e-05	6.19e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—HRAS—gallbladder cancer	4.23e-05	6.16e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—gallbladder cancer	4.21e-05	6.14e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—KRAS—gallbladder cancer	4.09e-05	5.97e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—gallbladder cancer	4.08e-05	5.95e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—HRAS—gallbladder cancer	4.08e-05	5.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—KRAS—gallbladder cancer	4.05e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NRAS—gallbladder cancer	4.04e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—gallbladder cancer	4.04e-05	5.9e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—gallbladder cancer	3.98e-05	5.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—gallbladder cancer	3.97e-05	5.8e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—gallbladder cancer	3.92e-05	5.72e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—gallbladder cancer	3.88e-05	5.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—gallbladder cancer	3.86e-05	5.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—gallbladder cancer	3.83e-05	5.59e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—gallbladder cancer	3.81e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—gallbladder cancer	3.7e-05	5.39e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—gallbladder cancer	3.69e-05	5.37e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—gallbladder cancer	3.67e-05	5.35e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—gallbladder cancer	3.62e-05	5.29e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—gallbladder cancer	3.6e-05	5.25e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—gallbladder cancer	3.5e-05	5.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—gallbladder cancer	3.49e-05	5.09e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—gallbladder cancer	3.48e-05	5.08e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—gallbladder cancer	3.48e-05	5.08e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—gallbladder cancer	3.44e-05	5.02e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—gallbladder cancer	3.42e-05	4.99e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—gallbladder cancer	3.38e-05	4.93e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—gallbladder cancer	3.3e-05	4.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—gallbladder cancer	3.28e-05	4.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—gallbladder cancer	3.23e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—gallbladder cancer	3.19e-05	4.65e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—gallbladder cancer	3.12e-05	4.55e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—gallbladder cancer	3.09e-05	4.51e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—gallbladder cancer	3.08e-05	4.49e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—gallbladder cancer	3.04e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—gallbladder cancer	3.01e-05	4.39e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—gallbladder cancer	2.99e-05	4.35e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—gallbladder cancer	2.97e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—gallbladder cancer	2.96e-05	4.32e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—gallbladder cancer	2.94e-05	4.29e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—gallbladder cancer	2.91e-05	4.24e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—gallbladder cancer	2.9e-05	4.22e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—gallbladder cancer	2.8e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—gallbladder cancer	2.8e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—gallbladder cancer	2.78e-05	4.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—gallbladder cancer	2.72e-05	3.97e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—gallbladder cancer	2.65e-05	3.86e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—gallbladder cancer	2.64e-05	3.85e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—gallbladder cancer	2.57e-05	3.75e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—gallbladder cancer	2.56e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—gallbladder cancer	2.49e-05	3.64e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—gallbladder cancer	2.36e-05	3.45e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—gallbladder cancer	2.35e-05	3.43e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—gallbladder cancer	2.28e-05	3.33e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—gallbladder cancer	2.26e-05	3.3e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—gallbladder cancer	2.25e-05	3.28e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—gallbladder cancer	2.22e-05	3.23e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—gallbladder cancer	2.18e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—gallbladder cancer	2.12e-05	3.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—gallbladder cancer	2.06e-05	3.01e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—gallbladder cancer	1.95e-05	2.84e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—gallbladder cancer	1.73e-05	2.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—gallbladder cancer	1.66e-05	2.41e-05	CbGpPWpGaD
